LLY Latest Press Releases

-- June 14, 2026 --

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL PRNewswire 3:15 AM

-- June 13, 2026 --

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting PRNewswire 11:15 AM

-- June 10, 2026 --

Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable PRNewswire 9:30 AM

-- June 9, 2026 --

FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis PRNewswire 6:19 PM

Convatec and Lilly Foundation Commit $5m to Partners In Health to Improve Care for Non-communicable Disease and Chronic Conditions Business Wire 4:00 AM

-- June 8, 2026 --

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials PRNewswire 2:30 PM

-- June 7, 2026 --

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause PRNewswire 11:00 AM

-- June 6, 2026 --

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications PRNewswire 2:30 PM

-- June 2, 2026 --

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting PRNewswire 9:30 AM

-- June 1, 2026 --

Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode Globe Newswire 9:05 AM

-- May 31, 2026 --

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer PRNewswire 8:01 AM

-- May 28, 2026 --

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care PRNewswire 1:00 PM

Foundayo and Zepbound now covered for millions of Americans PRNewswire 6:45 AM

-- May 27, 2026 --

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference PRNewswire 11:15 AM

-- May 26, 2026 --

Lilly announces three acquisitions to build infectious disease portfolio PRNewswire 6:45 AM

-- May 25, 2026 --

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia PRNewswire 8:45 AM

-- May 21, 2026 --

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting PRNewswire 5:00 PM

Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets Globe Newswire 9:00 AM

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial PRNewswire 6:45 AM

-- May 18, 2026 --

Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference PRNewswire 10:00 AM

-- May 16, 2026 --

Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth PRNewswire 11:00 AM

-- May 14, 2026 --

Lilly and UNICEF collaborate to give millions of children a healthier start PRNewswire 7:00 AM

-- May 12, 2026 --

Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials PRNewswire 6:01 PM

In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries PRNewswire 12:00 PM

Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates Globe Newswire 9:00 AM

-- May 11, 2026 --

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA Business Wire 12:43 PM

The Next Generation of the GLP-1 Revolution Is Already Underway Globe Newswire 8:30 AM

-- May 7, 2026 --

Biotech's Next Wave May Already be in Motion Globe Newswire 8:45 AM

-- May 5, 2026 --

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years PRNewswire 6:45 AM

-- May 4, 2026 --

Lilly declares second-quarter 2026 dividend PRNewswire 11:12 AM

-- April 30, 2026 --

Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines PRNewswire 6:45 AM

-- April 27, 2026 --

Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera PRNewswire 6:45 AM

-- April 23, 2026 --

The Longevity Trade Is No Longer a Buzzword - It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial Globe Newswire 6:15 AM

-- April 20, 2026 --

Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies PRNewswire 9:11 AM

-- April 16, 2026 --

Lilly confirms date and conference call for first-quarter 2026 financial results announcement PRNewswire 10:00 AM

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health PRNewswire 6:45 AM

-- April 13, 2026 --

Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL PRNewswire 6:45 AM

-- April 9, 2026 --

Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. PRNewswire 6:45 AM

-- April 1, 2026 --

FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions PRNewswire 11:33 AM

-- March 31, 2026 --

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA Business Wire 10:19 PM

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders PRNewswire 6:45 AM

-- March 28, 2026 --

Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity PRNewswire 3:15 PM

-- March 27, 2026 --

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis PRNewswire 9:00 AM

-- March 19, 2026 --

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes PRNewswire 6:45 AM

-- March 16, 2026 --

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis PRNewswire 6:45 AM

-- March 5, 2026 --

Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients PRNewswire 6:00 AM

-- March 3, 2026 --

Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight PRNewswire 5:31 PM

-- March 2, 2026 --

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 27, 2026 --

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata PRNewswire 8:12 AM

-- February 26, 2026 --

Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight PRNewswire 5:31 PM

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet PRNewswire 6:30 AM

-- February 23, 2026 --

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen PRNewswire 9:00 AM

-- February 19, 2026 --

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Ra, and Others | DelveInsight PRNewswire 5:31 PM

Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz) PRNewswire 12:15 PM

-- February 18, 2026 --

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight PRNewswire 6:45 AM

-- February 17, 2026 --

Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight PRNewswire 5:31 PM

Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company Business Wire 8:00 AM

-- February 16, 2026 --

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight PRNewswire 5:31 PM

Lilly to participate in TD Cowen's 46th Annual Health Care Conference PRNewswire 10:00 AM

USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company PRNewswire 8:00 AM

Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer PRNewswire 6:45 AM

-- February 11, 2026 --

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- February 9, 2026 --

Lilly to acquire Orna Therapeutics to advance cell therapies PRNewswire 7:00 AM

-- February 5, 2026 --

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX Business Wire 5:21 PM

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company's Directors and Officers for Breach of Fiduciary Duties - LLY Business Wire 4:00 PM

-- February 4, 2026 --

Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance PRNewswire 6:45 AM

-- January 30, 2026 --

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility PRNewswire 11:00 AM

-- January 23, 2026 --

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX PRNewswire 8:31 PM

-- January 22, 2026 --

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company's Directors and Officers for Breach of Fiduciary Duties - LLY Business Wire 10:00 AM

-- January 21, 2026 --

Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement PRNewswire 10:00 AM

-- January 20, 2026 --

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer PRNewswire 7:45 AM